Loading...
•
Dec 31, 2021
IRadimed Q4 2021 Earnings Report
Reported revenue growth of nearly 39% over the fourth quarter last year, supported by record bookings that grew over 48% from the fourth quarter last year.
Key Takeaways
iRadimed Corporation announced financial results for the three months and year ended December 31, 2021. Fourth quarter revenue grew nearly 39% over the fourth quarter last year and was supported by record bookings that grew over 48% from the fourth quarter last year.
Fourth quarter revenue grew nearly 39% over the fourth quarter last year.
Record bookings grew over 48% from the fourth quarter last year.
Net income was $3.9 million, or $0.31 per diluted share, compared to $0.6 million, or $0.05 per diluted share for the fourth quarter 2020.
Non-GAAP net income was $4.2 million, or $0.33 per diluted share, for the quarter ended December 31, 2021.
Revenue by Geographic Location
Forward Guidance
For the full year 2022, the Company expects to report revenue of $51.4 million to $52.2 million, GAAP diluted earnings per share of $0.82 to $0.90, and non-GAAP diluted earnings per share of $0.91 to $1.01, which assumes a normalized tax rate.
Positive Outlook
- Expects to report revenue of $51.4 million to $52.2 million for the full year 2022.
- GAAP diluted earnings per share of $0.82 to $0.90 expected for the full year 2022.
- Non-GAAP diluted earnings per share of $0.91 to $1.01 expected for the full year 2022.
- Expects to report revenue of $12.1 million to $12.3 million for the first quarter 2022.
- GAAP diluted earnings per share of $0.16 to $0.18 expected for the first quarter 2022.
Challenges Ahead
- Guidance assumes a normalized tax rate.
- Non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax.
- Potential disruptions in our limited supply chain for our products.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...